ConductScience.org, home

Gene · 951

CD37: CD37 molecule

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. CD37: CD37 molecule. Genes, record 951. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/951

On this page

Gene

Symbol
CD37
HGNC
Name
CD37 molecule
HGNC
NCBI Gene ID
951
NCBI Gene
HGNC ID
HGNC:1666
HGNC
Ensembl
ENSG00000104894
NCBI Gene
Aliases
GP52-40, TSPAN26
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
P11049Leukocyte antigen CD372810Ensembl, GeneID, HGNC

Source UniProt

Patents111

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
US 12600781 B22026-04-14438P11049Espacenet
EP 4699622 A12026-02-2518P11049Espacenet
JP 2026004568 A2026-01-1440556P11049Espacenet
WO 2025261963 A12025-12-2622P11049Espacenet
KR 1020250175330 A2025-12-1618P11049Espacenet
JP 2025529142 A2025-09-04811P11049Espacenet
JP 2025121994 A2025-08-2062P11049Espacenet
US 12371689 B22025-07-29811P11049Espacenet
US 12280021 B22025-04-2211P11049Espacenet
US 12275797 B22025-04-151P11049Espacenet

1 to 10 of 111

See all 111 patents

Drugs3

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
BI-836826CHEMBL4594531Leukocyte antigen CD37 inhibitorINHIBITORChEMBL
NARATUXIMAB EMTANSINECHEMBL2109268Leukocyte antigen CD37 binding agentBINDING AGENTChEMBL
OTLERTUZUMABCHEMBL3039539Leukocyte antigen CD37 binding agentBINDING AGENTChEMBL

Trials12

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT03343678BI-836826PHASE1ClinicalTrials.gov
NCT02759016BI-836826PHASE12020-07-24ClinicalTrials.gov
NCT02624492BI-836826PHASE22019-06-17ClinicalTrials.gov
NCT02564744NARATUXIMAB EMTANSINEPHASE22024-05-17ClinicalTrials.gov
NCT02538614BI-836826PHASE12020-11-25ClinicalTrials.gov
NCT01644253OTLERTUZUMABPHASE1ClinicalTrials.gov
NCT01534715NARATUXIMAB EMTANSINEPHASE1ClinicalTrials.gov
NCT01403948BI-836826PHASE12020-08-11ClinicalTrials.gov
NCT01317901OTLERTUZUMABPHASE12016-10-06ClinicalTrials.gov
NCT01296932BI-836826PHASE12020-08-20ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

NIH grants699

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleCD37 papersNewest fiscal year
P30CA008748Cancer Center Support Grant92025
P30CA016058Cancer Center Support Grant72025
P30CA016672Cancer Center Support Grant52025
P30CA012197Cancer Center Support Grant32025
P30CA015704Cancer Center Support Grant32025
P30CA023108Cancer Center Support Grant32025
P30CA118100University of New Mexico Cancer Center Support Grant32025
P50CA126752SPORE in Lymphoma32025
K12CA087723Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology22025
K12CA133250OSU K12 Training Grant in Oncology22025

1 to 10 of 699Source NIH's project files

See all 699 nih grants

Papers1,339

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
DuoHexaBody-CD37 induces direct cytotoxic signaling in diffuse large B-cell lymphoma.Elife202642474002PubTator, text miningPubMed
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.J Immunother Cancer202642413982PubTator, text miningPubMed
Radiometabolic Therapy in Lymphoma: From Radioimmunotherapy to Emerging Theranostic and Combination Strategies.Cancers (Basel)202642352493PubTator, text miningPubMed
Progressive suppression of regulated cell death defines terminal macrophage states in liver cirrhosis.Ann Med202642345211PubTator, text miningPubMed
The search for safe and effective CAR-T targets in AML.Blood Cancer J202642321183PubTator, text miningPubMed
C1q-targeting bispecific antibodies bypass Fc to trigger complement activation and receptor clustering agonism.Mol Immunol202642285030PubTator, text miningPubMed
A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies.J Hematol Oncol202642216090PubTator, text miningPubMed
Bispecific CD37-Siglec6 CAR‑T cells exhibit enhanced anti‑leukemic activity and reduced exhaustion in acute myeloid leukemia xenograft models.J Transl Med202642035126PubTator, text miningPubMed
Debio 1562M CD37-targeting ADC is highly active and well tolerated in preclinical models of AML and MDS.Cell Rep Med202642013843PubTator, text miningPubMed
Comparative proteomics reveals protein signatures shared between and unique to bona fide plant EVs and other plant-derived vesicles.Plant Physiol202641914509PubTator, text miningPubMed

1 to 10 of 1,339

See all 1,339 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/951

GET https://conductscience.org/api/genes/v1/951/patents?page=2